Lucia Lo Presti
University of Catania
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lucia Lo Presti.
The Journal of Sexual Medicine | 2011
Salvatore Caruso; Carmela Agnello; Mattea Romano; Stefano Cianci; Lucia Lo Presti; Chiara Malandrino; Antonio Cianci
INTRODUCTION A new oral contraceptive containing the natural estrogen estradiol and a 19-nortestosterone derivate dienogest (DNG) in a four-phasic 28-day regimen may be used by women. AIM To investigate the quality of sexual life of healthy women on estradiol valerate and DNG (E2V/DNG) oral contraceptive. METHODS Fifty-seven women (age range 18-48 years) were enrolled. The Short Form-36 (SF-36) questionnaire to assess quality of life (QoL) was administered at baseline and at the 26th day of both the 3rd and 6th cycles of oral contraceptive (OC) intake. The Short Personal Experience Questionnaire (SPEQ) to measure the change of sexual behavior was used at the 2nd, 7th, 14th, 21st, 26th, and 28th days of the baseline cycle, as well as at the same days of both the 3rd and 6th cycle of contraceptive intake. MAIN OUTCOME MEASURE The SF-36 and the SPEQ questionnaires. RESULTS Women reported QoL improvement at the 3rd (P < 0.05) and at the 6th cycles (P < 0.01). By SPEQ, improvement of sexuality during the 3rd and the 6th cycle with respect to baseline experience was observed (P < 0.05). The frequency of sexual activity remained basically unchanged (P = NS). Enjoyment and desire improved at the 6th cycle with respect to the 3rd cycle (P < 0.05). All women reported decreased dyspareunia at the 3rd and 6th cycles (P < 0.05). Interestingly, desire, arousal, orgasm, enjoyment, and sexual activity improved, reaching a peak around the 14th day of the menstrual cycle (P < 0.05). At the 3rd and 6th cycle, women on OCs were sexually cyclic, but the peak improvement of desire, arousal, orgasm, enjoyment, and sexual activity appeared around the 7th day of OC intake (P < 0.05). CONCLUSION Reduced hormone-free interval is a new concept in low-dose OC regimens. Moreover, the E2V/DNG multiphasic extended regimen has been found to positively modify the sexuality of users.
The Journal of Sexual Medicine | 2011
Salvatore Caruso; Marco Iraci Sareri; Carmela Agnello; Mattea Romano; Lucia Lo Presti; Chiara Malandrino; Antonio Cianci
INTRODUCTION Women may use new oral contraceptives (OC) having flexible extended-cycle regimens with a reduced hormone-free interval. AIM To study the changes of the quality of sexual life in users of the traditional 21/7 or extended-cycle 24/4 OC regimens both containing 3 mg drospirenone and 20 µg ethinyl estradiol. METHODS One hundred fifteen women (age range 18-37 years) were enrolled. Fifty-four women were randomly placed on traditional OC standard regimen, administered for 21 days, followed by a 7-day hormone-free interval (group A); and 61 women were placed on extended-cycle OC regimen covering 24 days of the cycle with a 4-day hormone-free interval (group B). The Short Form-36 (SF-36) validate questionnaire to assess quality of life (QoL) and the Short Personal Experience Questionnaire (SPEQ) to measure the changes of sexual behavior were administered before starting OC intake and at the 3rd and 6th cycle follow-ups. MAIN OUTCOME MEASURE The SF-36 and the SPEQ questionnaires. RESULTS Group A women reported QoL improvement during the 6th cycle on all the scales (P < 0.05). Group B women reported QoL improvement during the 3rd and 6th cycle (P < 0.05). Satisfaction with sexual activity, arousal, orgasm, and desire increased during the 3rd cycle in women on the group B (P < 0.05). Group A women did not report any change in all SPEQ items. At the 6th cycle, group B women reported better sexual experience than baseline in all SPEQ items (P < 0.05). All subjects who were affected by dyspareunia before OC intake reported decreased genital pain associated with intercourse at the 3rd and 6th cycle of both OC regimens (P < 0.05). CONCLUSION Women could use OCs in a subjective flexible modality. The extended-cycle OC might produce positive effects on the quality of sexual life, enforcing the concept of tailoring an OC to a woman.
The Journal of Sexual Medicine | 2014
Salvatore Caruso; Carmela Agnello; Chiara Malandrino; Lucia Lo Presti; Carla Cicero; Stefano Cianci
INTRODUCTION In mammals, the effects of ovarian steroids influence sexual behavior. In humans, there are a few studies that take into account if ovulation occurs. AIM The study aims to investigate if a womans sexuality changes during the week and over the menstrual cycle, and if so, in what way. METHODS This is a prospective cohort study; 1,957 heterosexual women were involved over the period January 2004-December 2011. Two subgroups were taken into consideration, women having a partner and singles. MAIN OUTCOME MEASURE Sexual interview and the Female Sexual Function Index and Female Sexual Distress Scale questionnaires were used to exclude women with sexual dysfunction. Women with ovulation confirmed by sonography were enrolled. Women were given diary cards on which to report their daily sexual activity. Serum concentrations of estradiol, progesterone, total testosterone, sex hormone binding globulin, and free androgen index were measured during the follicular, periovular, and luteal phase of the menstrual cycle. RESULTS One thousand one hundred eighty women (age range 18-40 years) were included in the analyses. Of them, 925 had a heterosexual relationship and 255 were single. Women with a partner had more sexual activity during the weekend, while the singles had a constant sexual activity over the week. The sexual activity of singles was higher during the ovulatory phase and lower during menses than that of the women with a partner. A linear correlation between sexual activity and androgenic hormonal profile during the menstrual cycle in women with and without a partner was observed. CONCLUSIONS Ovarian steroids modulate a womans sexual activity. This aspect was more evident in singles than in women having a partner, in which a variety of nonhormonal factors can have a role.
The Journal of Sexual Medicine | 2012
Salvatore Caruso; Carla Cicero; Mattea Romano; Lucia Lo Presti; Betty Ventura; Chiara Malandrino
INTRODUCTION Type 1 diabetic women may be affected by sexual dysfunction, mainly due to peripheral vascular disease. AIM To determine whether daily tadalafil 5 mg is effective in type 1 premenopausal women affected by sexual genital arousal disorder. METHOD Thirty-three volunteers were enrolled in a 12-week daily tadalafil 5 mg prospective study. MAIN OUTCOME MEASURES The efficacy of daily tadalafil 5 mg on sexual genital arousal (primary end point), and desire, orgasm, enjoyment and frequency of sexual activity, and genital pain (secondary end points) were assessed (i) subjectively by the Short Personal Experiences Questionnaire; and (ii) objectively by translabial color Doppler sonography of clitoral blood flow. Moreover, the Short Form-36 questionnaire was used to assess Quality of Life (QoL). RESULTS Thirty-two women completed the study. Women reported a QoL improvement at the 12th week follow-up (P<0.05). Tadalafil improved the experience of sexual genital arousal, and orgasm, sexual enjoyment, satisfaction by frequency of sexual activity, and frequency of sexual thoughts or fantasies (P<0.05). Finally, dyspareunia decreased with respect to baseline (P<0.001). After tadalafil administration, the mean peak systolic velocity increased and the mean diastolic velocity decreased from baseline (P<0.001). Moreover, the mean resistance index and the mean pulsatility index were significantly higher compared with baseline values (P<0.001). CONCLUSIONS Daily tadalafil 5 mg treatment seems to improve subjective sexual aspects and could be used to treat genital arousal disorder of premenopausal women with type 1 diabetes. The limits of the study were the small sample and the lack of a placebo control group.
Psychoneuroendocrinology | 1996
Filippo Drago; Francesco Di Leo; Sofia Ikonomou; Calogero Anzallo; Lina Busà; Lucia Lo Presti
Growth hormone (GH) secretion declines during normal aging along with reproductive activity in mammalian species. Various behavioral changes also occur in aged animals. In these experiments we have studied the effects of GH administration on behavioral and endocrine alterations exhibited by aged (18 months old) female rats of the Sprague-Dawley strain. Animals were selected showing at least 2 weeks of cornified vaginal smears (constant estrous) and treated with GH (0.1 mg/kg SC) daily for 8 weeks. Vaginal smears performed during the drug treatment revealed a recovery of estrous cycle in 60% of animals. GH treatment was also followed by an increased acquisition of shuttle-box active avoidance behavior and a facilitated retention of passive avoidance response. Compared to saline-injected controls, female rats treated with GH also exhibited a decrease of novelty-induced excessive grooming. The endocrine pattern of GH-treated aged female rats revealed a decrease in plasma prolactin levels and an increase in luteinizing hormone and 17 beta-estradiol levels as compared to those of control animals. These results support the concept that behavioral and endocrine alterations occurring in aging are not irreversible and that GH may interfere with these changes probably by means of its trophic action on different target organs.
European Journal of Obstetrics & Gynecology and Reproductive Biology | 2013
Salvatore Caruso; Stefano Cianci; Chiara Malandrino; Carla Cicero; Lucia Lo Presti; Antonio Cianci
OBJECTIVES To investigate the effects of a continuous-regimen combined oral contraceptive (COC) on hyperandrogenic women. STUDY DESIGN This prospective study enrolled 52 women with moderate to severe hirsutism, as well as acne and seborrhea. Women were placed on a 192-day continuous regimen. To assess hirsutism, the modified Ferriman-Gallwey (mF-G) scoring system was used. Acne and seborrhea were defined by the Cremoncini scale. Serum FSH, LH, estradiol, total testosterone, FAI, DHEAS, androstenedione, SHBG and fasting insulin were measured at baseline and at the endpoint. One-way ANOVA was used to compare serum hormone levels and hirsutism scores at baseline with those obtained at the endpoint. RESULTS A reduction of 78.5% in the mF-G scores was observed at the endpoint (p<0.001). Women underwent improvement of acne and seborrhea, -58.7% and -56%, respectively (p<0.001). An evident decrease in both total testosterone and FAI, and an increase in SHBG were shown (p<0.001). CONCLUSIONS A COC continuous-regimen improved the esthetic effect of hyperandrogenism.
Giornale Italiano di Ostetricia e Ginecologia | 2013
E. Casella; Betty Ventura; Giuliana Giunta; Maria Cariola; Lucia Lo Presti; C. Gallo; C.F. Tomaselli; Francesco Sapia; C. Comito; L.M. Castellano; G. Di Simone; Salvatore Caruso
Objective. We report an unusual case of ectopic pregnancy in a woman with right annessiectomy and left tubal ligation. Case report. A 35-year old woman underwent laparotomy right annessiectomy and left tubal ligations, because of a mature cystic teratoma attached to the right annex. She arrived in emergency three years later with lower abdominal pain, amenorrhea and a positive level of beta hCG (Beta subunit of human chorionic gonadotropin). An urgent videolaparoscopy was performed, with a left salpingectomy with the removal of the ectopic pregnancy in the distal remain tube. The pathologic report confirmed the diagnosis of ectopic pregnancy. The patient’s postoperative recovery was normal. Conclusion. The analysis of the literature/published data shows that the partial salpingectomy increases the risk of ectopic pregnancy, so total salpingectomy is the preferred option over partial salpingectomy, in order to reduce the risk of recurrent ectopic pregnancy.
Biology of Reproduction | 1982
Filippo Drago; Lucia Lo Presti; Filadelfo Nardo; Italo Panella; Mario Matera; U. Scapagnini
Archive | 2012
A. Tocco; C. Falduzzi; Lucia Lo Presti; Sebastiano Bandiera; D. Carpino; Carmelo Ferrauto; F. Lionti; K. Messina; S. Oddo; E. Sampugnaro; Marco Colizzi; Antonio Cianci
Archive | 2012
A. Tocco; Lucia Lo Presti; Sebastiano Bandiera; D. Carpino; Carmelo Ferrauto; F. Lionti; K. Messina; S. Oddo; E. Sampugnaro; Marco Colizzi